Derivatives and methods of treating hepatitis B infections

A compound of Formula III:

• or a pharmaceutically acceptable salt thereof, wherein
• Y is —C(O)—;
• R1 is —C(O)NRdRe, —C(O)NRdORe, or —C(O)NRdNRd;
• R2 is, at each occurrence, independently selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O —C1-C6-alkyl, and C1-C6-alkyl-OH;
• R3 is selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O —C1-C6-alkyl, and C1-C6-alkyl-OH;
• R4 is selected from (CR8R9)p-C1-C9-heteroaryl and (CR8R9)p-C6-C12-aryl, wherein heteroaryl and aryl are optionally substituted with 1, 2, or 3 groups, each independently selected from —OH, halo, CN, C1-C6-alkyl, C1-C6-haloalkyl, —O—C1-C6-alkyl, and C1-C6-alkyl-OH;
• R7 is selected from H, C1-C6-alkyl, and C1-C6-alkyl-OH;
• R8 is, at each occurrence, independently selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O—C1-C6-alkyl, and C1-C6-alkyl-OH;
• R9 is, at each occurrence, independently selected from H and C1-C6-alkyl;
• Rd is selected from H, C1-C6-alkyl, and C1-C6-alkyl-OH;
• Re is selected from H, C1-C6-alkyl, C1-C6-alkyl-OH, C1-C6-alkyl-OC1-C6-alkyl, C0-C6-alkyl-C3-C8-cycloalkyl, C2-C8-heterocyclyl, C6-C12-aryl, and C1-C9-heteroaryl, wherein cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with 1, 2, or 3 groups, each independently selected from —OH, halo, CN, C1-C6-alkyl, C1-C6-haloalkyl, and —O—C1-C6-alkyl;
• alternatively, Rd and Re are optionally joined to form a heterocyclic ring, which is optionally substituted with 1, 2, or 3 groups, each independently selected from —OH, halo, CN, C1-C6-alkyl, C1-C6-haloalkyl, and —O—C1-C6-alkyl;
• and
• p is 0, 1, 2, 3, or 4.